Navigation Links
Circassia's Rapid Grass Allergy Treatment Achieves Significant Symptom Reduction During Hay Fever Season
Date:10/1/2013

d the optimal short course of SPIRE therapy had significantly improved symptoms at the end of the season compared with those on placebo (p<0.05).  The treatment regimen was well tolerated, with a safety profile similar to placebo. Circassia plans to present the study results at a forthcoming leading scientific conference.

About grass allergy

Grass allergy, commonly referred to as hay fever, is extremely prevalent.  In Europe and the United States grasses are the most common cause of seasonal allergy, with approximately 15 - 25% of the population sensitised to pollen from different species.  Grass allergy can debilitate sufferers during the months when pollen is released, resulting in poor concentration, reduced performance and workplace and school absences.

About ToleroMune® technology

Circassia is developing a range of allergy treatments based on its novel, proprietary ToleroMune® technology.  This uses rationally-designed molecules identified from common allergens (Synthetic Peptide Immuno-Regulatory Epitopes; SPIREs) to generate regulatory T cells to control allergic responses and induce immune tolerance.  Circassia has achieved successful phase II results with its cat, house dust mite, ragweed and grass allergy therapies, and its cat allergy treatment entered phase III testing in October 2012.  

Clinical results show that short, simple courses of SPIRE allergy treatments can greatly reduce patients' allergic responses and improve symptoms over long periods, while proving extremely well tolerated.  As a result, SPIRE treatments offer major potential clinical benefits compared with existing therapies, and have significant market opportunities.  More than 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is valued at approximately $12 billion per year.  

About Ci
'/>"/>

SOURCE Circassia Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Global Demand for Pharmaceutical Regulatory Specialists Escalating Rapidly
2. Spartan Bioscience Receives FDA Clearance for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs
3. Managing Antibiotic-Resistant Bloodstream Infections with Rapid Molecular Diagnostics educational webinar hosted by Nanosphere and Xtalks
4. New Research on Rapid Identification and Strain Typing of Salmonella in Food to Be Presented at IAFP
5. PathoGenetix to Debut New Genotyping Technology for Rapid Strain Typing at IAFP
6. Rapid Identification and Strain Typing of Salmonella in Food Using Genome Sequence Scanning Technology
7. Report Shows Rapid Increase in Salaries for Life Science Jobs
8. PathoGenetix Advances Commercialization of New RESOLUTION Microbial Genotyping System for Rapid Bacterial Serotyping and Strain Typing
9. MedeAnalytics Ken Perez Predicts Rapid Growth of Healthcare Data Analytics Market at Conference on Data Analytics in Life Sciences, Healthcare and Biotech Companies
10. Isothermal Nucleic Acid Amplification Technologies Market 2012-2017: Molecular Diagnostics, Infectious Disease Testing, Blood Screening, Cancer Research, Rapid Testing
11. Life Technologies Offers New Rapid DNA Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... BROOK, NY (PRWEB) July 30, 2014 ... APDN), (Twitter: @APDN), a biotechnology firm that provides DNA-based ... Michael E. Hogan, Ph.D. Vice President of Life Sciences, ... mid-September. , Dr. Hogan will lead APDN’s ... form business relationships with biotech and healthcare customers, provide ...
(Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. ... received the Day 180 List of Outstanding Issues (LOI) ... for Human Use (CHMP) for the NB32 Marketing Authorization ... SR) is an investigational drug candidate being evaluated for ... earlier Day 120 time point were adequately addressed by ...
(Date:7/30/2014)... July 30, 2014  AtheroNova Inc. (OTCBB: AHRO), ... development of compounds to safely regress atherosclerotic plaque ... that its partner, CardioNova, has accomplished first dosing ... with AtheroNova,s lead compound, AHRO-001.  This Phase 1b ... Phase 1 safety trial completed in February 2014, ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... , EMERYVILLE, Calif. , June 1 Onyx Pharmaceuticals, ... 1 study of ONX 0912, an oral proteasome inhibitor, in patients with ... , , ... program and ONX 0912,s favorable preclinical profile – anti-tumor activity, safety and ...
... ... Consortium Using Systems Biology to Study Infectious Diseases , ... (PRWEB) June 1, 2010 -- Genedata, a leading ... it has been selected to participate in an ERA-Net-funded applied pathogenomics project, which is ...
... ... incorporating BioSoteria’s eLadder® Safety course series into its curriculum. The online drug safety ... pharmacovigilance, accessible to enrolled PharmD and PhD students, postdoctoral fellows, and residents via the ... ...
Cached Biology Technology:Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors 2Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors 3Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors 4Genedata Phylosopher Selected for ERA-NET sncRNA Project 2Genedata Phylosopher Selected for ERA-NET sncRNA Project 3Genedata Phylosopher Selected for ERA-NET sncRNA Project 4University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 2University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 3University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 4
(Date:7/30/2014)... The Governing Board of the Entomological Society of America ... for 2014. The election as a Fellow acknowledges outstanding ... following: research, teaching, extension, or administration. The following Fellows ... Annual Meeting -- which will be held November 16-19, ... BOSQUE-PREZ is a professor with the Department of ...
(Date:7/30/2014)... Press (OUP) is pleased to announce its new relationship ... 2015, OUP and CINP will partner to publish ... a fully open-access journal. , Alan Frazer, Editor-in-Chief of ... size and expertise of OUP will further facilitate the ... of the very leading journals within neuropsychopharmacology. The conversion ...
(Date:7/30/2014)... of biologists, led by Clemson University associate professor Andrew ... that will pave the way for novel anti-fouling paint ... medical and industrial applications. , The team,s findings, published ... last larval stage of barnacles that attaches to a ... polymeric material that acts as an underwater heavy-duty adhesive. ...
Breaking Biology News(10 mins):Entomological Society of America recognizes 2014 fellows 2Entomological Society of America recognizes 2014 fellows 3Entomological Society of America recognizes 2014 fellows 4Entomological Society of America recognizes 2014 fellows 5Entomological Society of America recognizes 2014 fellows 6Entomological Society of America recognizes 2014 fellows 7Entomological Society of America recognizes 2014 fellows 8Entomological Society of America recognizes 2014 fellows 9Entomological Society of America recognizes 2014 fellows 10Entomological Society of America recognizes 2014 fellows 11Entomological Society of America recognizes 2014 fellows 12Entomological Society of America recognizes 2014 fellows 13Entomological Society of America recognizes 2014 fellows 14Entomological Society of America recognizes 2014 fellows 15Entomological Society of America recognizes 2014 fellows 16Entomological Society of America recognizes 2014 fellows 17OUP to partner with the International College of Neuropsychopharmacology 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... battle against insect pests, new research indicates that it ... A group of Rockefeller University scientists who had previously ... smell in fruit flies now shows that this gene's ... insect species. , Research by Leslie Vosshall's laboratory had ...
... Researchers at the University of Bath have won a £261,000 ... of a designer drug that could stop influenza and some ... the grant comes at a time when fears are rising ... thousands of people. , Professor Ian Williams, of the Department ...
... researchers present a “cautionary tale?about what may go wrong when ... test for cancer. , In the February 16 issue of ... University of Texas M. D. Anderson Cancer Center detail why ... a small sample of blood is unlikely to lead to ...
Cached Biology News:Ancient olfaction protein is shared by many bugs, offering new pest control target 2Computers to be used to find blueprint for new influenza drug 2New species from old data 2New species from old data 3
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
Recombinant Rat PTX2/SAP...
Request Info...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
Biology Products: